Biosimilars are drug copies sharing the safety,
purity, and potency of the reference drugs.
However, they differ in terms of clinically inactive components without
any consequential implications. Biosimilars are considerably cost-efficient and
reduce the expenditure across healthcare systems. Biosimilars cost up to 30%
lesser than their parent product. This affordability allow them to be adopted
by various economies for the treatment of various diseases such as rheumatoid
arthritis, diabetes mellitus, cancers, lupus, etc.
These
drugs are used to treat a number of health problems such as blood hormone
deficiency, chronic and autoimmune disorders, growth hormone deficiency, and
oncology, among many other applications.
View summary of this report, Click Here
Biosimilar INFLECTRA
Pfizer company entered into an agreement with
Celltrion Inc., and Celltrion Healthcare, Co., Ltd., for various potential
biosimilars including INFLECTRA. Early April 2016, FDA (Food and Drug
Administration) approved Celltrion’s INFLECTRA. This is the first and only
biosimilar monoclonal antibody (mAb) therapy.
INFLECTRA
is a treatment indicated to reduce the signs and symptoms of adult ulcerative
colitis, adult and pediatric Crohn’s disease, ankylosing spondylitis, plaque
psoriasis, psoriatic arthritis, and rheumatoid arthritis (RA).
Biosimilar
Rubraca
FDA
granted an approval for Rubraca (rucaparib) to help in the treatment of
advanced ovarian cancer. The medicine is
prescribed for women under two or more chemotherapies and whose tumors have
reached a specific gene mutation (BRCA), either acquired (somatic) or inherited
(germline).
The next-generation-sequencing (NGS) test
detects the presence of the BRCA gene mutation in the patient’s tumor tissues
of the ovarian cancer. If one or more mutations are detected, the patient is
eligible for the Rubraca treatment.
Market
Overview
According
to a new report by Grand View Research, Inc., the biosimilars market is anticipated
to reach USD 41.7 billion by 2024. Cost –effectiveness of these drugs and the
encumbrance to reduce expenditure across healthcare systems globally is
predicted to drive the market.
Competitive Insight
Abbvie,
Inc.; Roche Diagnostics; Sandoz, Inc.; and Teva Pharmaceutical Industries Ltd.
are some of the key players of the biosimilars market
Sample Request Of These Report : https://goo.gl/wVLXTj
ConversionConversion EmoticonEmoticon